Physiomics PLC Updated Website

TIDMPYC

Physiomics PLC

11 June 2018

Physiomics Plc

("Physiomics" or "the Company")

Updated Website

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that following feedback from clients and shareholders it has today updated its website at http://www.physiomics-plc.com/.

The website address for the purposes of AIM Rule 26 remains unchanged.

In its recent placing announcement of the 23 May 2018, the Company stated its intention to improve its marketing approach, and the launch of the new site is a small but important step towards executing this goal.

Features of the upgraded site include:

   --     Fresher, cleaner more modern look and feel 
   --     Clearer, simpler descriptions of our services and technologies 
   --     Easier navigation and viewing on small personal devices 

-- Addition of mailing list functionality so investors and clients can sign up to receive news as it happens

-- Enhancement of Corporate Governance section to comply with forthcoming requirements for AIM quoted companies

   --     Updates to ensure compliance with GDPR 

Further features and functionality will be added going forwards so please watch this space!

For further information please contact:

Physiomics Plc

Dr Jim Millen

[phone]

WH Ireland Limited (nomad)

Katy Mitchell/James Sinclair-Ford

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

About Physiomics plc

Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by over 60 projects, involving over 25 targets and 60 drugs.

Based in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics' senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAEASKFFEDPEFF

(END) Dow Jones Newswires

June 11, 2018 11:05 ET (15:05 GMT)